急性肾损伤早期诊断生物标志物研究进展  

Progression of Biological Marker in Early Diagnosis Acute Kidney Injury:A Review

作　　者：肖燎原[1] 盛珺[1] 孙丽君[1] 梅长林[1] 

机构地区：[1]第二军医大学长征医院,上海200003

出　　处：《现代生物医学进展》2013年第16期3183-3185,共3页Progress in Modern Biomedicine

基　　金：国家自然科学基金青年项目(81100487)

摘　　要：急性肾损伤(acute kidney injury,AKI)既往称为急性肾衰竭"(acute renal failure,ARF),是一种常见的致死性肾病,在一般住院病人中AKI发病率约为5%,但在重症监护病房则高达30%～50%。内科疾病引起的AKI死亡率在23%左右,但由多脏器功能不全所致者死亡率高达60%。迄今,尚无有效治疗AKⅠ药物,一旦发生AKI,临床上只能采取支持治疗,等待肾功能的恢复。因此,早期诊断及早期治疗是防治AKI的最佳策略。生物标记物是近年来研究早期诊断AKI的热点和趋势,研究发现包括NGAL,KIM-1,IL-18,NHE3等多种标记物是早期预测AKI强力指标,本文就急性肾损伤早期诊断生物标志物研究进展进行综述。Acute kidney injury（AKI）,was also called acute renal failure（ARF）,is a common fatal nephropathy.Incidence rate of AKI on inpatients approximately 5%,but in ICU（intensive care unit）its more high,attain 30-50%.The mortality of AKI,which induction by internal medical disease approximately 23%,however,in MODS（multiple organ dysfunction）patients,the mortality reach up to 60%.Up to now,still has no active drug to treatment AKI,once to be sick,doctor can only give Supporting Therapy to wait for renal function recovery.So,early diagnosis is the best way in prevention and cure in AKI.For the past few years,the research of biological marker in early diagnosis is the hot spots and tendency,including NGAL,KIM-1,IL-18,NHE3 etc is found valuable in early diagnosis AKI.This review is about biological marker in early diagnosis AKI.

关 键 词：急性肾损伤 生物标记物 中性粒细胞明胶酶相关性脂质运载蛋白 肾损伤因子-1 白介素18 Na+ H+交换子同型体3 胱抑素C 富含半胱氨酸蛋白-61 

分 类 号：R692[医药卫生—泌尿科学]